This is not surprising as a clinical trial on a plant-derived VLP displaying influenza HA antigen has already demonstrated the VLP vaccine could elicit a higher CD4+ T cell response as well as a comparable CD8+ T cell response than a commercial inactivated vaccine (73). The gene discussed is CD8A; the disease is influenza.